Article Details
Retrieved on: 2024-02-05 19:03:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
Johnson & Johnson's experimental drug nipocalimab has shown promise in treating autoimmune diseases like Sjögren's syndrome and generalized myasthenia gravis, with potential for billions in sales. It represents a new class of anti-FcRn therapies.
Article found on: www.biopharmadive.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here